Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Horm Res Paediatr 2013;80:64-68
(DOI:10.1159/000351028)

Occurrence of Slipped Capital Femoral Epiphysis in Children Undergoing Gonadotropin-Releasing Hormone Agonist Therapy for the Treatment of Central Precocious Puberty

Inman M.a · Hursh B.E.b · Mokashi A.a, c · Pinto T.a, c · Metzger D.L.b · Cummings E.A.a, c

Author affiliations

aDepartment of Pediatrics, IWK Health Centre, Dalhousie University, Halifax, N.S., bDivision of Pediatric Endocrinology, BC Children's Hospital, University of British Columbia, Vancouver, B.C., and cDivision of Pediatric Endocrinology, IWK Health Centre, Dalhousie University, Halifax, N.S.,Canada

Corresponding Author

Elizabeth A. Cummings

Division of Pediatric Endocrinology, IWK Health Centre

PO Box 9700, 5850/5980 University Avenue

Halifax, NS B3K 6R8 (Canada)

E-Mail Elizabeth.cummings@dal.ca

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Background: Obesity, age and hormone imbalances including hypothyroidism and growth hormone deficiency and therapy, but not gonadotropin-releasing hormone agonist (GnRHa) therapy, have been identified as risk factors for slipped capital femoral epiphysis (SCFE). Five of 7 reported cases describe SCFE in children shortly after GnRHa therapy cessation. Methods: We report 3 cases of SCFE that occurred in children on GnRHa therapy for the treatment of central precocious puberty (CPP) and discuss possible promoting factors. Results: An otherwise healthy 8.75-year-old girl [body mass index (BMI) Z score +1.75] developed SCFE 6.75 years into GnRHa therapy for idiopathic CPP. A second girl (with a history of acute lymphoblastic leukemia requiring total body irradiation) was 10.6 years old (BMI Z score +1.06) when she developed SCFE 3.3 years into GnRHa therapy. The third case was an 8.75-year-old female with CPP secondary to a hypothalamic hamartoma (BMI Z score +1.65) who developed bilateral SCFE 5.6 years into therapy. Conclusion: Increasing evidence suggests an association between GnRHa therapy for CPP and the occurrence of SCFE. We suggest that a lack of adequate sex hormone exposure at a ‘critical period' of bone formation may result in a weakened epiphysis that becomes susceptible to slipping.

© 2013 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Novel Insights from Clinical Practice

Received: January 10, 2013
Accepted: March 28, 2013
Published online: July 13, 2013

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 1

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: http://www.karger.com/HRP


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.